Evidence map›Paper›PMID 26744317›Full record

ArticleOncotarget2016

Down-regulation of the zinc-finger homeobox protein TSHZ2 releases GLI1 from the nuclear repressor complex to restore its transcriptional activity during mammary tumorigenesis.

Miho Riku, Shingo Inaguma, Hideaki Ito, Takumi Tsunoda, Hiroshi Ikeda, Kenji Kasai

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Review
  15. Identification of NovelFrontiers in genetics · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Miho RikuDepartment of Pathology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Shingo InagumaDepartment of Pathology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Hideaki ItoDepartment of Pathology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Takumi TsunodaDepartment of Pathology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Hiroshi IkedaDepartment of Pathology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Kenji KasaiDepartment of Pathology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Aichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although breast cancer is one of the most common malignancies, the molecular mechanisms underlying its development and progression are not fully understood. To identify key molecules involved, we screened publicly available microarray datasets for genes differentially expressed between breast cancers and normal mammary glands. We found that three of the genes predicted in this analysis were differentially expressed among human mammary tissues and cell lines. Of these genes, we focused on the role of the zinc-finger homeobox protein TSHZ2, which is down-regulated in breast cancer cells. We found that TSHZ2 is a nuclear protein harboring a bipartite nuclear localization signal, and we confirmed its function as a C-terminal binding protein (CtBP)-dependent transcriptional repressor. Through comprehensive screening, we identified TSHZ2-suppressing genes such as AEBP1 and CXCR4, which are conversely up-regulated by GLI1, the downstream transcription factor of Hedgehog signaling. We found that GLI1 forms a ternary complex with CtBP2 in the presence of TSHZ2 and that the transcriptional activity of GLI1 is suppressed by TSHZ2 in a CtBP-dependent manner. Indeed, knockdown of TSHZ2 increases the expression of AEBP1 and CXCR4 in TSHZ2-expressing immortalized mammary duct epithelium. Concordantly, immunohistochemical staining of mammary glands revealed that normal duct cells expresses GLI1 in the nucleus along with TSHZ2 and CtBP2, whereas invasive ductal carcinoma cells, which does not express TSHZ2, show the increase in the expression of AEBP1 and CXCR4 and in the cytoplasmic localization of GLI1. Thus, we propose that down-regulation of TSHZ2 is crucial for mammary tumorigenesis via the activation of GLI1.

Indexed as

Gene Expression Regulation, NeoplasticApoptosisBlotting, WesternBreastBreast NeoplasmsCarboxypeptidasesCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCase-Control StudiesCell ProliferationCells, CulturedCell Transformation, NeoplasticFemaleHumansImmunoenzyme TechniquesAEBP1 protein, humanCarboxypeptidasesCXCR4 protein, humanGLI1 protein, humanReceptors, CXCR4Repressor ProteinsRNA, MessengerZinc Finger Protein GLI1AEBP1breast cancerCXCR4GLI1TSHZ2

Identifiers

PMID26744317
PMCPMC4868714
OpenAlexW2281108010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.